Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 3, 2008, Pages 245-252

  Gandhi, Malay S ^a   Deshmukh, Prajwal A ^a   Kamalov, German ^a   Zhao, Tieqiang ^a   Zhao, Wenyuan ^a   Whaley, Jonathan T ^a   Tichy, Jill R ^a   Bhattacharya, Syamal K ^a   Ahokas, Robert A ^a   Sun, Yao ^a   Gerling, Ivan C ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acetazolamide; Aldosteronism; Oxidative stress; Zinc; Zinc supplement

Indexed keywords

8 ISOPROSTANE; ACETAZOLAMIDE; ALDOSTERONE; BICARBONATE; MALONALDEHYDE; METALLOTHIONEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SULFADIAZINE ZINC; ZINC; CALCIUM; MAGNESIUM; ZINC SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE; HOMEOSTASIS; HYPERALDOSTERONISM; HYPOCALCEMIA; MALE; METABOLIC ALKALOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINARY EXCRETION; URINE ACIDIFICATION; VASCULAR FIBROSIS; VASCULITIS; VITAMIN SUPPLEMENTATION; ZINC DEFICIENCY; ZINC URINE LEVEL; ANIMAL; CHEMISTRY; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECT; HEART MUSCLE CELL; METABOLISM; NECROSIS; PATHOPHYSIOLOGY; PH; SPRAGUE DAWLEY RAT; URINE;

ACETAZOLAMIDE; ALDOSTERONE; ANIMALS; CALCIUM; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HOMEOSTASIS; HYDROGEN-ION CONCENTRATION; HYPERALDOSTERONISM; MAGNESIUM; MALE; METALLOTHIONEIN; MYOCYTES, CARDIAC; NECROSIS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; URINE; ZINC; ZINC SULFATE;

EID: 58149218447     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181833eb8     Document Type: Article

References (50)

1. Hambidge M. Human zinc deficiency. J Nutr. 2000;130 (5S Suppl): 1344S-1349S.
2. Maret W, Krezel A. Cellular zinc and redox buffering capacity of metallothionein/thionein in health and disease. Mol Med. 2007;13:371-375.
3. Prasad AS, Fitzgerald JT, Hess JW, et al. Zinc deficiency in elderly patients. Nutrition. 1993;9:218-224.
4. Tubek S. Role of zinc in regulation of arterial blood pressure and in the etiopathogenesis of arterial hypertension. Biol Trace Elem Res. 2007;117: 39-51.
5. Kosar F, Sahin I, Acikgoz N, et al. Significance of serum trace element status in patients with rheumatic heart disease: a prospective study. Biol Trace Elem Res. 2005;107:1-10.
6. Ripa S, Ripa R, Giustiniani S. Are failured cardiomyopathies a zinc-deficit related disease? A study on Zn and Cu in patients with chronic failured dilated and hypertrophic cardiomyopathies. Minerva Med. 1998;89:397-403.
7. Oster O. Trace element concentrations (Cu, Zn, Fe) in sera from patients with dilated cardiomyopathy. Clin Chim Acta. 1993;214:209-218.
8. Topuzoglu G, Erbay AR, Karul AB, et al. Concentrations of copper, zinc, and magnesium in sera from patients with idiopathic dilated cardiomy-opathy. Biol Trace Elem Res. 2003;95:11-17.
9. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
10. Koren-Michowitz M, Dishy V, Zaidenstein R, et al. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. Am J Hypertens. 2005;18:358-363.
11. Singal PK, Khaper N, Farahmand F, et al. Oxidative stress in congestive heart failure. Curr Cardiol Rep. 2000;2:206-211.
12. Yndestad A, Holm AM, Müller F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res. 2003;60:141-146.
13. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/ anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526-534.
14. Anker SD, Clark AL, Teixeira MM, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. 1999;83: 612-615.
15. Thomas M, Vidal A, Bhattacharya SK, et al. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. Am J Physiol Heart Circ Physiol. 2007;293:H2361-H2366.
16. 65zinc translocation in a rat model of chronic aldosteronism. J Cardiovasc Pharmacol. 2008;51:359-364.
17. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287:H2023-H2026.
18. Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res. 2003;93:e124-e135.
19. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimu-latory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 2003;285:H813-H821.
20. Welbourne TC, Francoeur D. Influence of aldosterone on renal ammonia production. Am J Physiol. 1977;233:E56-E60.
21. Ali MM, Frei E, Straub J, et al. Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. Toxicology. 2002;179:85-93.
22. Antila H, Salo M, Nanto V, et al. Serum iron, zinc, copper, selenium, and bromide concentrations after coronary bypass operation. J Parenter Enteral Nutr. 1990;14:85-89.
23. Bobillier-Chaumont S, Maupoil V, Berthelot A. Metallothionein induction in the liver, kidney, heart and aorta of cadmium and isoproterenol treated rats. J Appl Toxicol. 2006;26:47-55.
24. Song Y, Wang J, Li Y, et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol. 2005;167:17-26.
25. Feng W, Benz FW, Cai J, et al. Metallothionein disulfides are present in metallothionein-overexpressing transgenic mouse heart and increase under conditions of oxidative stress. J Biol Chem. 2006;281:681-687.
26. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113:544-554.
27. Crawford AJ, Bhattacharya SK. Excessive intracellular zinc accumulation in cardiac and skeletal muscles of dystrophic hamsters. Exp Neurol. 1987; 95:265-276.
28. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997; 35:138-147.
29. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
30. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871-878.
31. Vidal A, Sun Y, Bhattacharya SK, et al. The calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290:H286-H294.
32. Arroyo M, LaGuardia SP, Bhattacharya SK, et al. Micronutrients in African-Americans with decompensated and compensated heart failure. Transl Res. 2006;148:301-308.
33. Lester JW, Gannaway KF, Reardon RA, et al. Effects of adenosine and protein kinase C stimulation on mechanical properties of rat cardiac myocytes. Am J Physiol. 1996;271:H1778-H1785.
34. Haase H, Hebel S, Engelhardt G, et al. Flow cytometric measurement of labile zinc in peripheral blood mononuclear cells. Anal Biochem. 2006; 352:222-230.
35. Sun Y, Ratajska A, Weber KT. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med. 1995;126:95-101.
36. Gekle M, Silbernagl S, Oberleithner H. The mineralocorticoid aldosterone activates a proton conductance in cultured kidney cells. Am J Physiol. 1997;273:C1673-C1678.
37. Lemann J Jr, Gray RW, Maierhofer WJ, et al. The importance of renal net acid excretion as a determinant of fasting urinary calcium excretion. Kidney Int. 1986;29:743-746.
38. Massry SG, Coburn JW, Chapman LW, et al. The effect of long-term desoxycorticosterone acetate administration on the renal excretion of calcium and magnesium. J Lab Clin Med. 1968;71:212-219.
39. Cappuccio FP, Markandu ND, MacGregor GA. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron. 1988;48:280-283.
40. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab. 1962;22:1187-1192.
41. LaGuardia SP, Dockery BK, Bhattacharya SK, et al. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332:112-118.
42. Rossi E, Sani C, Perazzoli F, et al. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884-893.
43. Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol. 2000;59:95-104.
44. Agay D, Anderson RA, Sandre C, et al. Alterations of antioxidant trace elements (Zn, Se, Cu) and related metallo-enzymes in plasma and tissues following burn injury in rats. Burns. 2005;31: 366-371.
45. Karagulova G, Yue Y, Moreyra A, et al. Protective role of intracellular zinc in myocardial ischemia/reperfusion is associated with preservation of protein kinase C isoforms. J Pharmacol Exp Ther. 2007;321: 517-525.
46. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 1994;14:219-231.
47. Sun Y, Ahokas RA, Bhattacharya SK, et al. Oxidative stress in aldosteronism. Cardiovasc Res. 2006;71:300-309.
48. 2+ and H2O2 in peripheral blood mononuclear cells. Circulation. 2005;111:51-57.
49. Weglicki WB, Mak IT, Stafford RE, et al. Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition. Mol Cell Biochem. 1994;130:103-109.
50. Jacob C, Maret W, Vallee BL. Ebselen, a selenium-containing redox drug, releases zinc from metallothionein. Biochem Biophys Res Commun. 1998; 248:569-573.